The outcome of stem cell therapy in autism is remarkably positive. 91% of individuals with autism have shown clinical improvements including a decrease in aggressive behavior  and hyperactivity, improved eye contact and attention span, improvements in communication and social skills are observed.

Improvements are also reported in the PET CT scan of the brain as change in metabolic activity of the brain. These changes correlate to the clinical improvements confirming the positive effect of stem cell therapy in autism.

There are currently no established practice guidelines for treating the characteristics of autism with stem cell therapy. This means the treatment can vary across clinics.

 

Generally, the therapy process involves the following stages:

Pre-treatment checks: before starting the therapy, the patient might have blood tests, medical history checks and other physical checks to work out whether they’re a good candidate for the therapy.

Collection: the types of stem cells and the way they’re collected and prepared varies. For example, stem cells can be collected from donor placentas, umbilical cords or bone marrow. They can also be collected directly from the patient’s own bone marrow, fat or cerebrospinal fluid. This can be a painful and invasive procedure.

Cultivation: after collection, some stem cells might need to grow in a laboratory for a few weeks.

Injection: the cells are injected into the patient’s vein or spinal canal. This can be a painful and invasive procedure. The patient might need to have an anesthetic and/or be admitted to hospital. Depending on the clinic and the patient, there might be multiple stem cell injections over a period of days, weeks or months.

Follow-up: there are usually follow-up appointments after each treatment.

The consultancy board of “The Healer Stem Cell” including Histology &Embryology Professors, Plastic Surgeons, Psychologists and Physiotherapists  is very experienced in stemm cell therapies in autistic children and we have obtained promising results over the years.

NEURODEGENERATIVE DISEASES

Mesenchymal Stem Cell Therapies for Neurodegenerative Diseases

While there have been significant advances in the symptomatic management of these diseases that improve quality of life and at times survival, the available medications likely only slow the progression of neuronal death by a few months. The idea of using cell therapy to treat neurodegenerative diseases has been around for decades, most notably in Parkinson's Disease where a variety of cell transplant investigations have been performed with success.

According to a recent study conducted by Nathan P. Staff et al,

"The precise mechanism by which MSCs may exert beneficial effects in neurological disease is still being elucidated, but it appears that multiple different mechanisms may contribute. First, MSCs have been shown to secrete neurotrophic growth factors, including glial cell-derived neurotrophic factor (GDNF), vascular endothelial growth factor, and brain-derived neurotrophic factor (BDNF),which can be further enhanced under specific culture conditions. Neurotrophic growth factors have been shown to improve neuronal survival in a number of preclinical models of neuron injury, including ALS, PD, and MSA transgenic animals and nerve injury models. ‍ Second, MSCs strongly modulate the immune system and can aid wound healing, and this mechanism has been exploited in disorders such as graft versus host disease and Crohn’s disease. From a neurodegenerative perspective, it has become increasingly recognized that neuroinflammation plays a significant role."

Studies show promising results

"Considering the ability of MSCs to secrete neurotrophic factors, modulate inflammation, and possibly even act as mitochondria “donor”, it comes as no surprise that there is a lot of interest in the use of MSCs in the treatment of Parkinson’s Disease, and a multitude of animal studies has shown promise. Treatments have resulted in improvement of motor function, protection of the nigrostriatal system, and improved striatal dopamine release in several studies using toxic lesion rodent models of Parkinson’s Disease. Similar effects were reported with umbilical cord-derived MSCs with or without prior differentiation. For example, a recent study reported improvement of motor function, reduced microglial activation, and decreased loss of TH immunoreactivity, associated with local production of trophic factors.

‍